Exchange Traded Concepts’s Protagonist Therapeutics PTGX Stock Holding History

Exchange Traded Concepts’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.96M	Buy	24,124 +351	+1%	+$36.7K	0.01%	595
2026 Q1	$2.51M	Sell	23,773 -11,266	-32%	-$998K	0.02%	546
2025 Q4	$3.06M	Buy	35,039 +1,487	+4%	+$122K	0.02%	500
2025 Q3	$2.23M	Sell	33,552 -13,839	-29%	-$787K	0.02%	541
2025 Q2	$2.62M	Buy	47,391 +19,999	+73%	+$960K	0.03%	432
2025 Q1	$1.32M	Buy	27,392 +26,367	+2,572%	+$1.1M	0.02%	471
2024 Q4	$39.6K	Buy	1,025 +64	+7%	+$2.79K	﹤0.01%	1239
2024 Q3	$43.2K	Buy	+961	New	+$38.8K	﹤0.01%	1209

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Exchange Traded Concepts's PTGX Position: Q2 2026 in Review

Exchange Traded Concepts increased its Protagonist Therapeutics (PTGX) stake by 1.5% in Q2 2026, buying an estimated $36.7K and bringing the position to 24,124 shares worth $2.96M. The position accounts for 0.01% of the portfolio, ranked #595.

Exchange Traded Concepts first reported a position in PTGX in Q3 2024 and has held it in 8 quarters since. The position peaked at $3.06M in Q4 2025. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Exchange Traded Concepts held 24,124 shares of Protagonist Therapeutics worth $2.96M as of Q2 2026.
Exchange Traded Concepts bought 351 Protagonist Therapeutics shares in Q2 2026, an estimated $36.7K.
Protagonist Therapeutics made up 0.01% of Exchange Traded Concepts's portfolio in Q2 2026, its #595 holding.
Exchange Traded Concepts first reported a position in Protagonist Therapeutics in Q3 2024 and has held it in 8 quarters since.
Exchange Traded Concepts's Protagonist Therapeutics position peaked at $3.06M in Q4 2025.
344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Exchange Traded Concepts's 13F filing for Q2 2026, filed 22 Jul 2026.